High-dose fulvestrant as third-line endocrine therapy for breast cancer metastasis to the left kidney: A case report and literature review
Endocrine therapy plays an important role in the treatment of patients with hormone receptor-positive breast cancer. Renal metastasis of breast cancer is rare in clinical practice. We present here a 54-year-old woman with breast cancer after first line chemotherapy and second line endocrinotherapy (...
Gespeichert in:
| Veröffentlicht in: | Medicine (Baltimore) 2018-06, Vol.97 (24), p.e11115-e11115 |
|---|---|
| Hauptverfasser: | , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | e11115 |
|---|---|
| container_issue | 24 |
| container_start_page | e11115 |
| container_title | Medicine (Baltimore) |
| container_volume | 97 |
| creator | Xia, Dandan Wang, Huiyu Wang, Runjie Liu, Chaoying Xu, Junying |
| description | Endocrine therapy plays an important role in the treatment of patients with hormone receptor-positive breast cancer. Renal metastasis of breast cancer is rare in clinical practice.
We present here a 54-year-old woman with breast cancer after first line chemotherapy and second line endocrinotherapy (i.e., toremifene & exemestane) failure.
The patient was rarely diagnosed breast cancer metastasis to the kidney and a positive hormone status (ER and PR) but was negative for human epidermal factor receptor 2 (HER2).
The patient was treated with a high dose of fulvestrant (SERD; 500 mg) by intramuscular injection once per month.
The patient's condition significantly improved as measured by a decrease in the renal and pulmonary masses; symptoms including dry cough and blood phlegm also improved.
Endocrinotherapy with high-dose fulvestrant may provide benefits for patients with HR+/HER2- advanced breast cancer with renal metastasis after SERMs failure. |
| doi_str_mv | 10.1097/MD.0000000000011115 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6023661</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2055614321</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3552-ba47dedc1214f7932f530a290972fcbcf82384bc58eb543f64d812286691e3cb3</originalsourceid><addsrcrecordid>eNpdkU1v1DAQhi0EokvhFyAhH7mk-DsJB6SqBYrUigucLccZN6beeLGdXe1f4FfjZUv5mIvt8fs-Y88g9JKSM0r69s3N5Rn5E7SGfIRWVHLVyF6Jx2hFCJNN27fiBD3L-VsV8ZaJp-iE9T2hiosV-nHlb6dmjBmwW8IWcklmLthkXCafxib4GTDMY7TpsCsTJLPZYxcTHhKYXLA1s4WE11DqyWRfnfGgwwFcwXd-nGH_Fp9XXa2RYBNTxc8jDr5UVlnSIbv1sHuOnjgTMry4X0_R1w_vv1xcNdefP366OL9uLJeSNYMR7QijpYwK1_acOcmJYX1tCXN2sK5jvBODlR0MUnCnxNhRxjqlegrcDvwUvTtyN8uwriCY65-D3iS_Nmmvo_H635vZT_o2brUijCtFK-D1PSDF70ttmV77bCEEM0NcsmZESkUFZwcpP0ptijkncA9lKNGHKeqbS_3_FKvr1d8vfPD8HlsViKNgF0PtYr4Lyw6SnsCEMv3iybZnDSO0I4pK0tSMYvwn-MqqYw</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2055614321</pqid></control><display><type>article</type><title>High-dose fulvestrant as third-line endocrine therapy for breast cancer metastasis to the left kidney: A case report and literature review</title><source>MEDLINE</source><source>DOAJ Directory of Open Access Journals</source><source>Wolters Kluwer Open Health</source><source>IngentaConnect Free/Open Access Journals</source><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><source>Alma/SFX Local Collection</source><creator>Xia, Dandan ; Wang, Huiyu ; Wang, Runjie ; Liu, Chaoying ; Xu, Junying</creator><creatorcontrib>Xia, Dandan ; Wang, Huiyu ; Wang, Runjie ; Liu, Chaoying ; Xu, Junying</creatorcontrib><description>Endocrine therapy plays an important role in the treatment of patients with hormone receptor-positive breast cancer. Renal metastasis of breast cancer is rare in clinical practice.
We present here a 54-year-old woman with breast cancer after first line chemotherapy and second line endocrinotherapy (i.e., toremifene & exemestane) failure.
The patient was rarely diagnosed breast cancer metastasis to the kidney and a positive hormone status (ER and PR) but was negative for human epidermal factor receptor 2 (HER2).
The patient was treated with a high dose of fulvestrant (SERD; 500 mg) by intramuscular injection once per month.
The patient's condition significantly improved as measured by a decrease in the renal and pulmonary masses; symptoms including dry cough and blood phlegm also improved.
Endocrinotherapy with high-dose fulvestrant may provide benefits for patients with HR+/HER2- advanced breast cancer with renal metastasis after SERMs failure.</description><identifier>ISSN: 0025-7974</identifier><identifier>EISSN: 1536-5964</identifier><identifier>DOI: 10.1097/MD.0000000000011115</identifier><identifier>PMID: 29901634</identifier><language>eng</language><publisher>United States: The Authors. Published by Wolters Kluwer Health, Inc. All rights reserved</publisher><subject>Antineoplastic Agents, Hormonal - administration & dosage ; Antineoplastic Combined Chemotherapy Protocols - therapeutic use ; Breast Neoplasms - drug therapy ; Breast Neoplasms - pathology ; Clinical Case Report ; Estradiol - administration & dosage ; Estradiol - analogs & derivatives ; Female ; Fulvestrant ; Humans ; Kidney - pathology ; Kidney Neoplasms - drug therapy ; Kidney Neoplasms - secondary ; Lung Neoplasms - secondary ; Middle Aged ; Receptors, Estrogen ; Receptors, Progesterone ; Tomography, X-Ray Computed</subject><ispartof>Medicine (Baltimore), 2018-06, Vol.97 (24), p.e11115-e11115</ispartof><rights>The Authors. Published by Wolters Kluwer Health, Inc. All rights reserved.</rights><rights>Copyright © 2018 the Author(s). Published by Wolters Kluwer Health, Inc. 2018</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c3552-ba47dedc1214f7932f530a290972fcbcf82384bc58eb543f64d812286691e3cb3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC6023661/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC6023661/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,864,885,27924,27925,53791,53793</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/29901634$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Xia, Dandan</creatorcontrib><creatorcontrib>Wang, Huiyu</creatorcontrib><creatorcontrib>Wang, Runjie</creatorcontrib><creatorcontrib>Liu, Chaoying</creatorcontrib><creatorcontrib>Xu, Junying</creatorcontrib><title>High-dose fulvestrant as third-line endocrine therapy for breast cancer metastasis to the left kidney: A case report and literature review</title><title>Medicine (Baltimore)</title><addtitle>Medicine (Baltimore)</addtitle><description>Endocrine therapy plays an important role in the treatment of patients with hormone receptor-positive breast cancer. Renal metastasis of breast cancer is rare in clinical practice.
We present here a 54-year-old woman with breast cancer after first line chemotherapy and second line endocrinotherapy (i.e., toremifene & exemestane) failure.
The patient was rarely diagnosed breast cancer metastasis to the kidney and a positive hormone status (ER and PR) but was negative for human epidermal factor receptor 2 (HER2).
The patient was treated with a high dose of fulvestrant (SERD; 500 mg) by intramuscular injection once per month.
The patient's condition significantly improved as measured by a decrease in the renal and pulmonary masses; symptoms including dry cough and blood phlegm also improved.
Endocrinotherapy with high-dose fulvestrant may provide benefits for patients with HR+/HER2- advanced breast cancer with renal metastasis after SERMs failure.</description><subject>Antineoplastic Agents, Hormonal - administration & dosage</subject><subject>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</subject><subject>Breast Neoplasms - drug therapy</subject><subject>Breast Neoplasms - pathology</subject><subject>Clinical Case Report</subject><subject>Estradiol - administration & dosage</subject><subject>Estradiol - analogs & derivatives</subject><subject>Female</subject><subject>Fulvestrant</subject><subject>Humans</subject><subject>Kidney - pathology</subject><subject>Kidney Neoplasms - drug therapy</subject><subject>Kidney Neoplasms - secondary</subject><subject>Lung Neoplasms - secondary</subject><subject>Middle Aged</subject><subject>Receptors, Estrogen</subject><subject>Receptors, Progesterone</subject><subject>Tomography, X-Ray Computed</subject><issn>0025-7974</issn><issn>1536-5964</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2018</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpdkU1v1DAQhi0EokvhFyAhH7mk-DsJB6SqBYrUigucLccZN6beeLGdXe1f4FfjZUv5mIvt8fs-Y88g9JKSM0r69s3N5Rn5E7SGfIRWVHLVyF6Jx2hFCJNN27fiBD3L-VsV8ZaJp-iE9T2hiosV-nHlb6dmjBmwW8IWcklmLthkXCafxib4GTDMY7TpsCsTJLPZYxcTHhKYXLA1s4WE11DqyWRfnfGgwwFcwXd-nGH_Fp9XXa2RYBNTxc8jDr5UVlnSIbv1sHuOnjgTMry4X0_R1w_vv1xcNdefP366OL9uLJeSNYMR7QijpYwK1_acOcmJYX1tCXN2sK5jvBODlR0MUnCnxNhRxjqlegrcDvwUvTtyN8uwriCY65-D3iS_Nmmvo_H635vZT_o2brUijCtFK-D1PSDF70ttmV77bCEEM0NcsmZESkUFZwcpP0ptijkncA9lKNGHKeqbS_3_FKvr1d8vfPD8HlsViKNgF0PtYr4Lyw6SnsCEMv3iybZnDSO0I4pK0tSMYvwn-MqqYw</recordid><startdate>20180601</startdate><enddate>20180601</enddate><creator>Xia, Dandan</creator><creator>Wang, Huiyu</creator><creator>Wang, Runjie</creator><creator>Liu, Chaoying</creator><creator>Xu, Junying</creator><general>The Authors. Published by Wolters Kluwer Health, Inc. All rights reserved</general><general>Wolters Kluwer Health</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20180601</creationdate><title>High-dose fulvestrant as third-line endocrine therapy for breast cancer metastasis to the left kidney: A case report and literature review</title><author>Xia, Dandan ; Wang, Huiyu ; Wang, Runjie ; Liu, Chaoying ; Xu, Junying</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3552-ba47dedc1214f7932f530a290972fcbcf82384bc58eb543f64d812286691e3cb3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2018</creationdate><topic>Antineoplastic Agents, Hormonal - administration & dosage</topic><topic>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</topic><topic>Breast Neoplasms - drug therapy</topic><topic>Breast Neoplasms - pathology</topic><topic>Clinical Case Report</topic><topic>Estradiol - administration & dosage</topic><topic>Estradiol - analogs & derivatives</topic><topic>Female</topic><topic>Fulvestrant</topic><topic>Humans</topic><topic>Kidney - pathology</topic><topic>Kidney Neoplasms - drug therapy</topic><topic>Kidney Neoplasms - secondary</topic><topic>Lung Neoplasms - secondary</topic><topic>Middle Aged</topic><topic>Receptors, Estrogen</topic><topic>Receptors, Progesterone</topic><topic>Tomography, X-Ray Computed</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Xia, Dandan</creatorcontrib><creatorcontrib>Wang, Huiyu</creatorcontrib><creatorcontrib>Wang, Runjie</creatorcontrib><creatorcontrib>Liu, Chaoying</creatorcontrib><creatorcontrib>Xu, Junying</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Medicine (Baltimore)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Xia, Dandan</au><au>Wang, Huiyu</au><au>Wang, Runjie</au><au>Liu, Chaoying</au><au>Xu, Junying</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>High-dose fulvestrant as third-line endocrine therapy for breast cancer metastasis to the left kidney: A case report and literature review</atitle><jtitle>Medicine (Baltimore)</jtitle><addtitle>Medicine (Baltimore)</addtitle><date>2018-06-01</date><risdate>2018</risdate><volume>97</volume><issue>24</issue><spage>e11115</spage><epage>e11115</epage><pages>e11115-e11115</pages><issn>0025-7974</issn><eissn>1536-5964</eissn><abstract>Endocrine therapy plays an important role in the treatment of patients with hormone receptor-positive breast cancer. Renal metastasis of breast cancer is rare in clinical practice.
We present here a 54-year-old woman with breast cancer after first line chemotherapy and second line endocrinotherapy (i.e., toremifene & exemestane) failure.
The patient was rarely diagnosed breast cancer metastasis to the kidney and a positive hormone status (ER and PR) but was negative for human epidermal factor receptor 2 (HER2).
The patient was treated with a high dose of fulvestrant (SERD; 500 mg) by intramuscular injection once per month.
The patient's condition significantly improved as measured by a decrease in the renal and pulmonary masses; symptoms including dry cough and blood phlegm also improved.
Endocrinotherapy with high-dose fulvestrant may provide benefits for patients with HR+/HER2- advanced breast cancer with renal metastasis after SERMs failure.</abstract><cop>United States</cop><pub>The Authors. Published by Wolters Kluwer Health, Inc. All rights reserved</pub><pmid>29901634</pmid><doi>10.1097/MD.0000000000011115</doi><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0025-7974 |
| ispartof | Medicine (Baltimore), 2018-06, Vol.97 (24), p.e11115-e11115 |
| issn | 0025-7974 1536-5964 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6023661 |
| source | MEDLINE; DOAJ Directory of Open Access Journals; Wolters Kluwer Open Health; IngentaConnect Free/Open Access Journals; EZB-FREE-00999 freely available EZB journals; PubMed Central; Alma/SFX Local Collection |
| subjects | Antineoplastic Agents, Hormonal - administration & dosage Antineoplastic Combined Chemotherapy Protocols - therapeutic use Breast Neoplasms - drug therapy Breast Neoplasms - pathology Clinical Case Report Estradiol - administration & dosage Estradiol - analogs & derivatives Female Fulvestrant Humans Kidney - pathology Kidney Neoplasms - drug therapy Kidney Neoplasms - secondary Lung Neoplasms - secondary Middle Aged Receptors, Estrogen Receptors, Progesterone Tomography, X-Ray Computed |
| title | High-dose fulvestrant as third-line endocrine therapy for breast cancer metastasis to the left kidney: A case report and literature review |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-29T02%3A32%3A41IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=High-dose%20fulvestrant%20as%20third-line%20endocrine%20therapy%20for%20breast%20cancer%20metastasis%20to%20the%20left%20kidney:%20A%20case%20report%20and%20literature%20review&rft.jtitle=Medicine%20(Baltimore)&rft.au=Xia,%20Dandan&rft.date=2018-06-01&rft.volume=97&rft.issue=24&rft.spage=e11115&rft.epage=e11115&rft.pages=e11115-e11115&rft.issn=0025-7974&rft.eissn=1536-5964&rft_id=info:doi/10.1097/MD.0000000000011115&rft_dat=%3Cproquest_pubme%3E2055614321%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2055614321&rft_id=info:pmid/29901634&rfr_iscdi=true |